Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M13ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLMVItKSzVyPUCuNFI5ODZizszN NV3HXmo6W0GQR1XS
KS-1 M{SwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;TeGlEPTB;MD6wN|g{PSEQvF2= MYDTRW5ITVJ?
TE-11 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXHTWM2OD1yLkC3PFIzKM7:TR?= NV3Re4tXW0GQR1XS
EW-1 NWfSdVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnhZWs5UUN3ME2wMlA5PTh3IN88US=> MX\TRW5ITVJ?
HMV-II M4K5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrY[49KSzVyPUCuNFg5PDZizszN MXnTRW5ITVJ?
COLO-205 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jQ[mlEPTB;MD6xNFQ2PCEQvF2= M371VXNCVkeHUh?=
ES1 M1:2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLHTWM2OD1yLkGwOlk3KM7:TR?= NIm1fnlUSU6JRWK=
GDM-1 NIXu[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyyWVZKSzVyPUCuNVM3PzJizszN MljRV2FPT0WU
ML-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTjTWM2OD1yLkG1PFk3KM7:TR?= NHvpUm5USU6JRWK=
Saos-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnSOI9KSzVyPUCuNVY2OjZizszN MoPvV2FPT0WU
NCI-H1355 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfWTWM2OD1yLkG4NVM2KM7:TR?= NEW4blZUSU6JRWK=
G-401 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;a[np{UUN3ME2wMlE5OjNizszN NHH2WWRUSU6JRWK=
EW-16 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\rS2lEPTB;MD6xPFc4PyEQvF2= NY\KT4JzW0GQR1XS
EW-7 MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[0OnVKSzVyPUCuNVg5QDFizszN MmW5V2FPT0WU
NCI-H727 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfZWIZKSzVyPUCuNVk4QTRizszN NFfJ[oVUSU6JRWK=
LCLC-97TM1 M4jMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMkC5OVUh|ryP M4XCN3NCVkeHUh?=
NCI-H650 NYezSXo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLFTWM2OD1yLkKxN|g1KM7:TR?= NVzoW2JSW0GQR1XS
NCI-H2122 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTUeIdKSzVyPUCuNlMzQTlizszN MUfTRW5ITVJ?
SK-N-DZ NWjpc2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPhTWM2OD1yLkKzOlk5KM7:TR?= NInWfIlUSU6JRWK=
HT-29 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGToe4dKSzVyPUCuNlQzPDhizszN M{ezUnNCVkeHUh?=
LB771-HNC Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzwTWM2OD1yLkK1PVE2KM7:TR?= M4fISnNCVkeHUh?=
HT-144 M1fhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMk[xPVEh|ryP NFTYSmdUSU6JRWK=
LAN-6 NXTMSG5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMk[zOFgh|ryP MUjTRW5ITVJ?
EW-18 M3XRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjw[4RtUUN3ME2wMlI4ODBzIN88US=> MnXJV2FPT0WU
LS-1034 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOxcG5WUUN3ME2wMlI4OTN{IN88US=> NHH2S45USU6JRWK=
EW-11 NGnDRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jYTGlEPTB;MD6yPFQ{OiEQvF2= M4rDN3NCVkeHUh?=
SNU-C1 Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMkmzNVMh|ryP M16w[nNCVkeHUh?=
RS4-11 NXz1Z3pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwM{O3OVgh|ryP M4PSdHNCVkeHUh?=
ES4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPhTWJSUUN3ME2wMlQyODN6IN88US=> NV7mWo1OW0GQR1XS
COLO-320-HSR NXTqb3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr0TWM2OD1yLkSxN|Y5KM7:TR?= NYTrbpFZW0GQR1XS
NB10 NU\q[mNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL4VItEUUN3ME2wMlQ2PDN5IN88US=> MljyV2FPT0WU
BFTC-905 M2nj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XkN2lEPTB;MD60Olc2QCEQvF2= NH\iTZhUSU6JRWK=
A375 M1PrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwNEe2NVch|ryP NVzEToFPW0GQR1XS
SJRH30 NYTIOHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwNUC4NlIh|ryP M4DiOnNCVkeHUh?=
NOS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7ucWJtUUN3ME2wMlUzOjZ5IN88US=> MWPTRW5ITVJ?
SIG-M5 M1XQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLORZpKSzVyPUCuOVM2PTdizszN NYfnfnBwW0GQR1XS
DOK Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPl[nVKSzVyPUCuOVU3KM7:TR?= NXTw[5Y{W0GQR1XS
NB69 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfD[JlmUUN3ME2wMlU5OjV5IN88US=> MkTMV2FPT0WU
SK-NEP-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn64TWM2OD1yLk[wNlM3KM7:TR?= NVvCWoc1W0GQR1XS
SK-MM-2 M2HVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLOTWM2OD1yLk[1OFkyKM7:TR?= MVHTRW5ITVJ?
NCI-H358 M3fndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjUPVhKSzVyPUCuOlcxQDJizszN M1\0[nNCVkeHUh?=
RH-1 NG\UNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr0fJd2UUN3ME2wMlc1QDV7IN88US=> MYLTRW5ITVJ?
NH-12 NHHvUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHQTWM2OD1yLke2NFQ3KM7:TR?= NFLCZpBUSU6JRWK=
TE-12 NHfQclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X1fmlEPTB;MD63OlQ5PiEQvF2= MmX1V2FPT0WU
COLO-668 NXzRfnBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwOES2OlYh|ryP MXzTRW5ITVJ?
PANC-08-13 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwOE[zO|ch|ryP NWfwR2JzW0GQR1XS
HCC2998 NWLyOFd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHT[VVOUUN3ME2wMlg5OjZ|IN88US=> MUnTRW5ITVJ?
ABC-1 NGe4VHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu5W3lKSzVyPUCuPVA{PTJizszN NXfmT4VuW0GQR1XS
ES6 M2nDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\1TlFiUUN3ME2wMlkyODZ4IN88US=> NXjrXVltW0GQR1XS
SNU-387 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXFTWM2OD1yLkm5N|k{KM7:TR?= NHnpSWtUSU6JRWK=
CMK NXj2d|FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvLTWM2OD1yLkm5PVI6KM7:TR?= MX\TRW5ITVJ?
SJSA-1 NYXPRXpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vPemlEPTB;MT6wN|Y2OyEQvF2= NY\sUllXW0GQR1XS
SIMA M3\IcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwME[4NlUh|ryP MYfTRW5ITVJ?
ES3 NHLUTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1Tm1KSzVyPUGuNVIzQTdizszN MXfTRW5ITVJ?
IGROV-1 NUnqemltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\0NGlEPTB;MT6xOVQ1PCEQvF2= M3\SZ3NCVkeHUh?=
MEL-JUSO NVjLWXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKxTWM2OD1zLkG1O|U6KM7:TR?= MX;TRW5ITVJ?
T84 M3zCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwMkC5NVQh|ryP NVrCVpdyW0GQR1XS
CAL-85-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fXNWlEPTB;MT6yN|E{QCEQvF2= M2XVbXNCVkeHUh?=
RD NWLNU2plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonyTWM2OD1zLkK2OFU2KM7:TR?= M{\sXnNCVkeHUh?=
TE-8 NWTvT2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki4TWM2OD1zLkOxOFYzKM7:TR?= NX;TW4pDW0GQR1XS
L-363 M3zPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLFVoVwUUN3ME2xMlM1OjB6IN88US=> NU\IWop2W0GQR1XS
EKVX NHvjXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonVTWM2OD1zLkO0OVY5KM7:TR?= MkPXV2FPT0WU
SK-MEL-3 M1G0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnjbox1UUN3ME2xMlQ5PTV4IN88US=> NVTN[oZpW0GQR1XS
TGBC24TKB NYf2UY5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwNUCxPVMh|ryP MYXTRW5ITVJ?
NCI-H1770 NE[3blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjpcZhsUUN3ME2xMlUyOTF|IN88US=> MmLkV2FPT0WU
HuH-7 NEjrUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwNkCwPVgh|ryP MVTTRW5ITVJ?
HL-60 NF3Qb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\TTWM2OD1zLk[2PVI5KM7:TR?= MX7TRW5ITVJ?
TE-1 NUTmTVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH64cWtKSzVyPUGuO|A6PDVizszN M2[0RXNCVkeHUh?=
LC-2-ad MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwN{O4PFch|ryP MlXvV2FPT0WU
LB647-SCLC M13qT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X4RWlEPTB;MT63OlU5OyEQvF2= MWLTRW5ITVJ?
NCI-H2171 NFO5SHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT6eWJKSzVyPUGuO|c4OTZizszN MULTRW5ITVJ?
SK-PN-DW MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwOUGyPVgh|ryP NFrBXHNUSU6JRWK=
MC-IXC NGPjOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HKUmlEPTB;MT65PFk5KM7:TR?= MXvTRW5ITVJ?
LS-513 M2jGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTLTWM2OD1{LkC1N|A2KM7:TR?= NXvLfGNoW0GQR1XS
EW-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJwMEm4OFQh|ryP MmriV2FPT0WU
OPM-2 M1\pRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJwMUCyJO69VQ>? NX;ibIdrW0GQR1XS
LP-1 M{jiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJwMkW4NFch|ryP M331c3NCVkeHUh?=
LU-134-A NVfTTIFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj2ZW5KSzVyPUKuNlc4KM7:TR?= MnnZV2FPT0WU
CP66-MEL NHizb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm4RXJKSzVyPUKuNlkxOTRizszN MULTRW5ITVJ?
HCC1143 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwNEWzOlgh|ryP M3;IR3NCVkeHUh?=
LOXIMVI Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHryZVJKSzVyPUKuOlAzOSEQvF2= MontV2FPT0WU
TE-10 M{jZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHPVWdKSzVyPUKuO|A5OzhizszN MlfiV2FPT0WU
NCI-H1882 NYmwTG9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLtfIlKSzVyPUKuO|UzOjdizszN NIq0OotUSU6JRWK=
CHP-126 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f6WmlEPTB;Mj63OlMyPyEQvF2= M2fiNXNCVkeHUh?=
NCI-H1623 NHSxcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr1TWM2OD1{LkmyNFI1KM7:TR?= MoPEV2FPT0WU
GB-1 NXywW5ptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwOUO0NFQh|ryP NGPEVXFUSU6JRWK=
RCC10RGB M1jjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO3VWdKSzVyPUKuPVUzQDFizszN MWHTRW5ITVJ?
NCI-H2141 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwOU[4PVYh|ryP MXfTRW5ITVJ?
GI-ME-N NIrTVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn0WolvUUN3ME2zMlAxPTZ3IN88US=> MUnTRW5ITVJ?
NCI-H526 M1Xybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK4PYxKSzVyPUOuNFQxQDVizszN NITZb4xUSU6JRWK=
NCI-H747 NFjlRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H2XGlEPTB;Mz6wOFk6OiEQvF2= NW\CZopuW0GQR1XS
SNU-423 NETyT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zvdmlEPTB;Mz6yNFMyOyEQvF2= MUnTRW5ITVJ?
A427 NWHOepFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfNT4hKSzVyPUOuNlU3QTlizszN M1jSRnNCVkeHUh?=
CAL-12T NWfNWY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTFWYx[UUN3ME2zMlQxPzF|IN88US=> NX7jO3NjW0GQR1XS
LU-99A NELSU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPS[lZKSzVyPUOuOFcyODVizszN MmH0V2FPT0WU
MS-1 NVvaNFlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXlU|JNUUN3ME2zMlU{PDJ7IN88US=> MoKyV2FPT0WU
SK-LU-1 M2XKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4faTmlEPTB;Mz63OlI6PSEQvF2= MUfTRW5ITVJ?
SW837 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUOyW4lJUUN3ME2zMlc3OzN|IN88US=> NX\UUI9ZW0GQR1XS
ES8 NY\vUHJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X3SmlEPTB;Mz64N|g4PyEQvF2= MYDTRW5ITVJ?
MZ2-MEL NHOybpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwOUKwPFYh|ryP NEnQZ2ZUSU6JRWK=
TGW MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3Ee2plUUN3ME20MlAyOzFzIN88US=> NVHp[XpIW0GQR1XS
GP5d NWXUNnFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfrNllKSzVyPUSuNFU{PjJizszN M3rTbXNCVkeHUh?=
BB49-HNC MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTYZ3lLUUN3ME20MlE2OjF|IN88US=> MWPTRW5ITVJ?
NB13 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjXNJlKSzVyPUSuNlY5QDdizszN MUXTRW5ITVJ?
NTERA-S-cl-D1 M1LIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ywO2lEPTB;ND6yPFYyPSEQvF2= Mkf1V2FPT0WU
NCI-H1648 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSxRYdKSzVyPUSuNlk5OTlizszN MVnTRW5ITVJ?
LCLC-103H M{PLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRwM{KxPVUh|ryP MY\TRW5ITVJ?
LS-411N M2fJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXLTWM2OD12LkS0PFg2KM7:TR?= NUnme4FnW0GQR1XS
NCI-H1092 NYTz[2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHoXJdKSzVyPUSuOFU3QDdizszN NVXmZpVYW0GQR1XS
PANC-10-05 NIn5SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfmOWdKSzVyPUSuOlk5PCEQvF2= MYrTRW5ITVJ?
DK-MG MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnnWpJ3UUN3ME20MlgxQTN|IN88US=> MVHTRW5ITVJ?
OVCAR-5 M4DNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj4SGQzUUN3ME20MlgyOjJ4IN88US=> M4H6W3NCVkeHUh?=
CAL-39 NH7ReYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHVTWM2OD12Lki3Olch|ryP M1nNTnNCVkeHUh?=
TE-441-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ThT2lEPTB;ND65NFU{PyEQvF2= M1vvXXNCVkeHUh?=
MOLT-16 NWOxd4ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwOUWyOVMh|ryP MlTQV2FPT0WU
MCF7 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDDOlZqUUN3ME21MlE1PTF5IN88US=> MkGwV2FPT0WU
CAPAN-1 NYDJVlc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjae5RKSzVyPUWuNlU4ODdizszN NX3zR45ZW0GQR1XS
PSN1 NV;4cmJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHWNoJKSzVyPUWuNlczOzVizszN NV[3c|Q4W0GQR1XS
NCI-H292 NHTSN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwM{CwOFQh|ryP MlPjV2FPT0WU
CPC-N M{nFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j2SGlEPTB;NT6zPVQyQSEQvF2= MlXtV2FPT0WU
DoTc2-4510 M{WwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTyRoI2UUN3ME21MlQ2OzdzIN88US=> M1qyZ3NCVkeHUh?=
LB1047-RCC M2fJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iyc2lEPTB;NT61OVk{OyEQvF2= MXHTRW5ITVJ?
MHH-ES-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPHbnRKSzVyPUWuOVk6ODdizszN MlHKV2FPT0WU
NMC-G1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle1TWM2OD13LkewNlI4KM7:TR?= MnnmV2FPT0WU
SW1710 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7sbJVFUUN3ME21Mlc1PzVzIN88US=> MnvEV2FPT0WU
YAPC NHPxZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTORWt{UUN3ME21Mlc3OjBzIN88US=> NWHyRnZJW0GQR1XS
22RV1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M135PGlEPTB;NT64NFAyQSEQvF2= NXnqOpBrW0GQR1XS
COLO-679 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTVwOEi5OFgh|ryP MYHTRW5ITVJ?
TCCSUP MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTVwOUOyOVkh|ryP M2\kOXNCVkeHUh?=
C2BBe1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrOTWM2OD13LkmzPVch|ryP NUT4fVZCW0GQR1XS
TE-15 NEO2Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS2UYh3UUN3ME22MlA3PjB3IN88US=> M2HMc3NCVkeHUh?=
SCLC-21H M4HpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD14LkGwPFQ{KM7:TR?= M1zOU3NCVkeHUh?=
EoL-1-cell MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrHO2s3UUN3ME22MlE3PTZ|IN88US=> Ml;CV2FPT0WU
NKM-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P2VWlEPTB;Nj6xOlcyKM7:TR?= M2LGR3NCVkeHUh?=
NCI-H1304 NYm0dYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHx[4pKSzVyPU[uNlc1OjhizszN MnywV2FPT0WU
NB6 NF:y[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HDVmlEPTB;Nj6yPVYzOiEQvF2= NE\WeXlUSU6JRWK=
NALM-6 NELPfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZwM{OyN{DPxE1? MXrTRW5ITVJ?
NCI-H522 M33GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXX[|hKSzVyPU[uN|M{ODZizszN M2DOV3NCVkeHUh?=
MV-4-11 M{m5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z5S2lEPTB;Nj6zO|A4QSEQvF2= MlXPV2FPT0WU
LB2241-RCC MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TxRmlEPTB;Nj6zPFY3PyEQvF2= Mlj4V2FPT0WU
NCI-H1417 NEH3WlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZwNEC4OFch|ryP MYjTRW5ITVJ?
HT-1197 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nIZ2lEPTB;Nj61O|EzOiEQvF2= NWnSUmxzW0GQR1XS
P30-OHK M1jNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\zdpRKSzVyPU[uOlI4PyEQvF2= NVHucG1{W0GQR1XS
ALL-PO MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfRcohvUUN3ME22MlcyQTF4IN88US=> NW\VTnRQW0GQR1XS
OVCAR-4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHkSHFtUUN3ME22Mlc2PDB3IN88US=> M4\5VnNCVkeHUh?=
HCC2157 NV62VnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj3TWM2OD14Lke3OFc2KM7:TR?= MV\TRW5ITVJ?
NCI-H838 MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDkWHlKSzVyPU[uPVY1QSEQvF2= Ml71V2FPT0WU
NCI-H1299 M13oUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm0TWM2OD14Lkm3NFkh|ryP NVXpT2ZZW0GQR1XS
SW954 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PMeGlEPTB;Nz6yNFA3QCEQvF2= NUHFSmVsW0GQR1XS
NCI-H441 NI\2VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX3TWM2OD15LkO0NFY2KM7:TR?= MnHmV2FPT0WU
SK-MEL-2 NEfRZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHCTWM2OD15LkS4N|c{KM7:TR?= Mn\NV2FPT0WU
KARPAS-45 NYiwclNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTdwNkW5Nlkh|ryP M{W0XnNCVkeHUh?=
CAL-54 NVzwW2RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLqNlVKSzVyPUeuPFI6PzdizszN MX\TRW5ITVJ?
KYSE-180 NInJUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnVZ2ViUUN3ME23Mlg5QTRzIN88US=> M2\kXHNCVkeHUh?=
NCI-H187 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLPXIcxUUN3ME23Mlk2QTR5IN88US=> NV6z[nVlW0GQR1XS
RT-112 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13EOWlEPTB;OD6wPVY4PyEQvF2= NFXiWJpUSU6JRWK=
NCI-H1437 NV3UeIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq2S2VKSzVyPUiuNFk4QTVizszN M2nPTnNCVkeHUh?=
SNU-449 MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HHO2lEPTB;OD6yPFI4OiEQvF2= M3fDR3NCVkeHUh?=
HCC1187 NX25cXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPWSVRKSzVyPUiuNlk{QTFizszN MkHjV2FPT0WU
NCI-H2030 M{nmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThwM{e3NVQh|ryP NHnFe|RUSU6JRWK=
HuO-3N1 M3TOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv3fVRKSzVyPUiuN|c5PDRizszN NHXsOpNUSU6JRWK=
COLO-792 M4\lXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3TTWM2OD16LkSxOVI4KM7:TR?= M1voR3NCVkeHUh?=
MIA-PaCa-2 NWjCVo0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRThwOEW1NFgh|ryP NHXVUmlUSU6JRWK=
SK-N-FI M1X2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG4PG9GUUN3ME25MlA1OjVizszN MV\TRW5ITVJ?
MMAC-SF MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LjZ2lEPTB;OT6wPVc2OSEQvF2= NH\hO4lUSU6JRWK=
NCI-H28 M1Sx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;KTWM2OD17LkGwOFY6KM7:TR?= NUHtV|N2W0GQR1XS
ETK-1 NGrQRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDYTWM2OD17LkK5PVc1KM7:TR?= NGfFd3hUSU6JRWK=
NCI-H1993 M4PHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoToTWM2OD17LkS0NlYyKM7:TR?= NVXjcZdLW0GQR1XS
no-11 M4jNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXXT|FKSzVyPUmuOFcyOiEQvF2= MmTiV2FPT0WU
ChaGo-K-1 NELFZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTlwNUG1PFMh|ryP NF2zXGhUSU6JRWK=
NCCIT MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTlwNUOxOlkh|ryP NVv4eIZEW0GQR1XS
SAS NHXMTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljITWM2OD1zMD6yOFgh|ryP NWS3PFlHW0GQR1XS
A673 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\wTWM2OD1zMD6zO|A1KM7:TR?= M{nSWXNCVkeHUh?=
NCI-H1522 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f6NGlEPTB;MUCuN|cxPyEQvF2= NXX2eFlVW0GQR1XS
NCI-H810 NHniPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFyLkO5NFch|ryP NH;Ze5pUSU6JRWK=
IST-MES1 M4jKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLCW3VJUUN3ME2xNE41PTZ2IN88US=> MoWyV2FPT0WU
GR-ST MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrhTWM2OD1zMD61NFI1KM7:TR?= MkTqV2FPT0WU
SUP-T1 NFjEZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFyLkezNVch|ryP NELCcXlUSU6JRWK=
NB5 NV7Y[HBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zNSmlEPTB;MUCuPVAzOiEQvF2= NVjvZ2RlW0GQR1XS
MZ1-PC NIrFXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS4d4p2UUN3ME2xNE46PTdzIN88US=> MUPTRW5ITVJ?
SK-CO-1 M3zESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDsTWM2OD1zMD65PVMyKM7:TR?= NEPzbZJUSU6JRWK=
Capan-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFzLkOxPVgh|ryP NFq2eZlUSU6JRWK=
697 NH74elFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELyZpRKSzVyPUGxMlY4PTdizszN M1HTcHNCVkeHUh?=
REH MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFzLke0OVEh|ryP M4LOdXNCVkeHUh?=
GI-1 M{m4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfvUpVWUUN3ME2xNU45PjF3IN88US=> NHO2XYZUSU6JRWK=
BB65-RCC M1HEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojlTWM2OD1zMj6wPVE3KM7:TR?= NUPBW2ViW0GQR1XS
NCI-H1651 NGPYSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELGWnZKSzVyPUGyMlI1PzhizszN MV\TRW5ITVJ?
NCI-H1618 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fYcGlEPTB;MUKuN|k4PiEQvF2= NEjWb3FUSU6JRWK=
NCI-H2081 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF{Lk[xOFEh|ryP MUXTRW5ITVJ?
GCIY NIH1RWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfFb2ZKSzVyPUGyMlczOTNizszN NUi5eWVDW0GQR1XS
NY MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF|LkC2OFMh|ryP MWnTRW5ITVJ?
PANC-03-27 NFv0fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF|LkC4NFch|ryP NH71W4FUSU6JRWK=
BHY NIfpe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TSbmlEPTB;MUOuNlEzOSEQvF2= NUSwe4tzW0GQR1XS
SK-OV-3 M37QZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv5OINKSzVyPUGzMlM4PjNizszN M1rVUnNCVkeHUh?=
5637 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XGUWlEPTB;MUOuO|c2QSEQvF2= MorLV2FPT0WU
LC-1F NIXIVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF2LkCzOVYh|ryP NH\zVVVUSU6JRWK=
SNB75 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;zTWM2OD1zND6wN|g{KM7:TR?= M1H3fnNCVkeHUh?=
CHP-212 M{G3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\xcXpKSzVyPUG0MlA1PjRizszN MlXaV2FPT0WU
HT-1376 M17wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm4cJVsUUN3ME2xOE4yOTJ4IN88US=> Mn3vV2FPT0WU
MONO-MAC-6 NEm2VlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF2LkG1NFIh|ryP MVnTRW5ITVJ?
CA46 NUDjdG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUeyXXpCUUN3ME2xOE4yQDJ5IN88US=> M2nKNHNCVkeHUh?=
SCC-15 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XvWWlEPTB;MUSuOVU5OyEQvF2= NGHIRZlUSU6JRWK=
ATN-1 M1TEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHny[5BKSzVyPUG0MlY3OjdizszN M1;SWXNCVkeHUh?=
NCI-H2405 MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nvWGlEPTB;MUSuPFE2PyEQvF2= MUTTRW5ITVJ?
NCI-H716 M4nEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPYTWM2OD1zND64OFk{KM7:TR?= Mk\0V2FPT0WU
SW620 NGjXSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvnTWM2OD1zND65NFE1KM7:TR?= MV7TRW5ITVJ?
NCI-H226 NHzESIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L3fWlEPTB;MUSuPVA5PSEQvF2= MmnUV2FPT0WU
SW962 NVjOWpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXGZ|FKSzVyPUG0Mlk1OzJizszN MWDTRW5ITVJ?
KYSE-150 M3LSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\qenFzUUN3ME2xOE46PTVizszN MVLTRW5ITVJ?
OCUB-M M2DSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPPOVlKSzVyPUG0Mlk5QDNizszN NWLkeo9DW0GQR1XS
ES7 NGnhfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF3LkC5PFQh|ryP NGPJVHJUSU6JRWK=
SW1463 NHH4UWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\pZpVKSzVyPUG1MlQzOjNizszN MV7TRW5ITVJ?
CAKI-1 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTRTYxKSzVyPUG1MlU{PDZizszN NVnhT2wzW0GQR1XS
MKN28 NFvGSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnmTHpuUUN3ME2xOU42PDd7IN88US=> MkXFV2FPT0WU
SW13 M2LoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[4[WlEPTB;MUWuOlE5KM7:TR?= MWrTRW5ITVJ?
A3-KAW MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr0TWM2OD1zNT65Olk4KM7:TR?= MVfTRW5ITVJ?
LU-65 M3PpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W0TGlEPTB;MUWuPVc3QCEQvF2= NFrLZWJUSU6JRWK=
Calu-1 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\PTWM2OD1zNj6wN|Y5KM7:TR?= M4PLRXNCVkeHUh?=
ST486 NEDBT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Gwb2lEPTB;MU[uNFQ{OSEQvF2= NYDUdGRqW0GQR1XS
BB30-HNC MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3QVoxKSzVyPUG2MlEzPDZizszN M{PUUXNCVkeHUh?=
EGI-1 NHfQdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPUXJFNUUN3ME2xOk41PDZizszN Mlr1V2FPT0WU
SH-4 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF4LkS3N|Eh|ryP M1;5NHNCVkeHUh?=
MN-60 MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LiNWlEPTB;MUeuNlI6PyEQvF2= MXvTRW5ITVJ?
MPP-89 NH24[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPUcmlKSzVyPUG3MlI1PTlizszN NG\0TYxUSU6JRWK=
A2780 NGDKVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF5LkSxN|kh|ryP M4n6W3NCVkeHUh?=
Daoy NHfuSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37Ze2lEPTB;MUeuOFY6PSEQvF2= NImzVJFUSU6JRWK=
NCI-H2126 M3vD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF5LkS3O|Eh|ryP NVTaWIZvW0GQR1XS
NCI-H1563 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnVTWM2OD1zNz60PVE4KM7:TR?= NUSyU3NmW0GQR1XS
8-MG-BA MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nyXGlEPTB;MUeuOlY1QCEQvF2= NEXiOFlUSU6JRWK=
786-0 M{DZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkTWM2OD1zNz64N|U{KM7:TR?= MlrIV2FPT0WU
AM-38 M4\4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zhT2lEPTB;MUeuPVMxPiEQvF2= M2SxTXNCVkeHUh?=
COLO-824 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDyRmVuUUN3ME2xPE41PDN4IN88US=> MUXTRW5ITVJ?
SK-MEL-30 NEnYZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPxTWM2OD1zOD61NFgzKM7:TR?= M13PO3NCVkeHUh?=
CESS NUPrV4p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3XTWM2OD1zOD63OlA6KM7:TR?= M2rL[nNCVkeHUh?=
BL-70 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF6LkixOVYh|ryP NUDPUYNSW0GQR1XS
NCI-H2170 M37SPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnYTWM2OD1zOD65NVc6KM7:TR?= NGW2d3NUSU6JRWK=
HT-3 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrqSHhKSzVyPUG4Mlk5OyEQvF2= MlP2V2FPT0WU
BOKU NVvxTG51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF7LkCzPFEh|ryP NV3HfYZPW0GQR1XS
HPAF-II M{D2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT4cppKSzVyPUG5MlMxOTVizszN MVrTRW5ITVJ?
KGN NVvzd454T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF7LkS3OlUh|ryP NYr6RVhxW0GQR1XS
MC-CAR NXTEZZBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\1WpVKSzVyPUG5MlY{OTNizszN MWLTRW5ITVJ?
BHT-101 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3NR2FPUUN3ME2xPU44PzdizszN NH\Jb3NUSU6JRWK=
SW1783 M3:1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPjcXRMUUN3ME2xPU44QDB4IN88US=> M4\pN3NCVkeHUh?=
KP-N-YN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT3VmxEUUN3ME2yNE4xOjZ{IN88US=> NV\NbWViW0GQR1XS
LU-165 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJyLkW1O|Eh|ryP NXywPY9LW0GQR1XS
GOTO NVfrSFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PsZmlEPTB;MkCuOlQ2OSEQvF2= NW\scopEW0GQR1XS
EFM-19 NHjpO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPLWFZKSzVyPUKxMlA4OTZizszN MXHTRW5ITVJ?
CTV-1 NEHCdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJzLkGwOVQh|ryP Mm\YV2FPT0WU
HEL NWjNV3NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJzLkSyNVYh|ryP NVvSWnppW0GQR1XS
SNU-C2B MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILN[mdKSzVyPUKxMlQzPiEQvF2= M{SyR3NCVkeHUh?=
ECC4 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jMN2lEPTB;MkGuO|A4KM7:TR?= M3jNfXNCVkeHUh?=
NEC8 NIXSRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICwd|BKSzVyPUKxMlg{PjhizszN MkPEV2FPT0WU
KMOE-2 NVLUVlU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULrdpRTUUN3ME2yNU45QTJzIN88US=> NWDtV5hXW0GQR1XS
NCI-H524 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XXWmlEPTB;MkKuNFgxQCEQvF2= NW[zboR6W0GQR1XS
WSU-NHL M{Hafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTxXWRMUUN3ME2yNk4yPTd5IN88US=> NHHt[VlUSU6JRWK=
SF126 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPBfIJKSzVyPUKyMlI1PjlizszN NGjHO5NUSU6JRWK=
HOP-92 M3XXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVftTHFUUUN3ME2yNk4{OTZ5IN88US=> M4S0fnNCVkeHUh?=
CTB-1 M2j5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXZXldKSzVyPUKyMlQ3PzdizszN NUfseIdKW0GQR1XS
KYSE-270 NFy3WpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq2TWM2OD1{Mj65N|U4KM7:TR?= NHP2VG5USU6JRWK=
SK-MEL-24 M{izXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj2TWM2OD1{Mz6xPFch|ryP NVnlbIt5W0GQR1XS
Calu-3 M4D1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDsOZBKSzVyPUKzMlIyOjhizszN M{i0XnNCVkeHUh?=
GAMG NX:xXmZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC0TWM2OD1{Mz6yN|Y4KM7:TR?= NI\Zd5NUSU6JRWK=
SW1573 NHriUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK4NnplUUN3ME2yN{44PDF3IN88US=> Mk[0V2FPT0WU
MHH-NB-11 M4fOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;zTWM2OD1{ND6wNVk1KM7:TR?= NGrv[JVUSU6JRWK=
TK10 MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzaco9KSzVyPUK0MlUxOTNizszN MWXTRW5ITVJ?
LB373-MEL-D MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHBVZlsUUN3ME2yOE43ODZ2IN88US=> M2DYcnNCVkeHUh?=
KALS-1 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP0bIpKSzVyPUK0Mlc{OjdizszN NFHMb|hUSU6JRWK=
HUTU-80 NIrEVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorFTWM2OD1{NT64NFMzKM7:TR?= MXHTRW5ITVJ?
HuP-T3 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHRSoNKSzVyPUK2MlE3PzRizszN NVfPXGVYW0GQR1XS
OE19 NY\Lc3A{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n0[GlEPTB;Mk[uNlE2OyEQvF2= MoTTV2FPT0WU
J82 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7x[VAxUUN3ME2yOk4zPDdzIN88US=> MY\TRW5ITVJ?
DU-4475 M2rTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ4LkO4NVkh|ryP NWfCXXFsW0GQR1XS
DMS-53 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ4LkWxN|gh|ryP MkLFV2FPT0WU
COLO-741 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3kZmlKSzVyPUK2Mlg{PDRizszN MmrVV2FPT0WU
SW48 NUWwVpV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjjfpJKSzVyPUK2Mlg5OiEQvF2= MV;TRW5ITVJ?
IGR-1 NGfReohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTBR4NKSzVyPUK2Mlk{OzRizszN MUnTRW5ITVJ?
639-V NEX0N5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vqXmlEPTB;MkeuNFI1PSEQvF2= M3[0PHNCVkeHUh?=
LK-2 NYKyNodxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ5LkSxOFEh|ryP NXLsfXI1W0GQR1XS
NCI-H2347 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDGTWM2OD1{Nz65Olk6KM7:TR?= M3;QbXNCVkeHUh?=
NCI-H2228 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjFTWM2OD1{OD6wPVA2KM7:TR?= NFLMeHNUSU6JRWK=
LS-123 NHjMR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ6LkGyOlIh|ryP M1\3e3NCVkeHUh?=
U031 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF24[3FKSzVyPUK4MlI2OiEQvF2= NHztXZpUSU6JRWK=
NCI-H1792 NEHhNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrkPFNKSzVyPUK4MlQ4OjFizszN NEWyPFJUSU6JRWK=
NCI-H2087 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmexTWM2OD1{OD63OVUzKM7:TR?= NWe2SFh4W0GQR1XS
NCI-H2342 M{PvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr2[pdNUUN3ME2yPU42OjB6IN88US=> NEfORVhUSU6JRWK=
SW626 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrBXpFKSzVyPUK5Mlc2PiEQvF2= MUDTRW5ITVJ?
LB2518-MEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHpUIRKSzVyPUK5MlgyPSEQvF2= M4TydnNCVkeHUh?=
RXF393 M4Xj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\XTWM2OD1|MD6wPVUzKM7:TR?= MX\TRW5ITVJ?
LC4-1 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNyLkOwPVIh|ryP NF;3[lhUSU6JRWK=
NCI-H1694 NFrQeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn1ZolGUUN3ME2zNE43PjJ2IN88US=> MkjVV2FPT0WU
K5 NYW0eGFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\5TWM2OD1|MD65O|AzKM7:TR?= NFOyPHlUSU6JRWK=
HDLM-2 NEL2WWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNyLkm3NlUh|ryP NHPIU4VUSU6JRWK=
BCPAP NYfuOXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKwTWM2OD1|MT64N|c6KM7:TR?= NH7neYpUSU6JRWK=
BC-3 NGHYWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rjVGlEPTB;M{KuNVQxOyEQvF2= MVrTRW5ITVJ?
LB996-RCC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vmZWlEPTB;M{KuNlM2QCEQvF2= M{PzXHNCVkeHUh?=
NCI-H2009 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PJNmlEPTB;M{KuOFk5OSEQvF2= MorRV2FPT0WU
HTC-C3 M{HmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O0S2lEPTB;M{OuO|UyQSEQvF2= NHfZeHVUSU6JRWK=
LAMA-84 M{G4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Ps[mlEPTB;M{SuOFQxPyEQvF2= NULuRod1W0GQR1XS
CCRF-CEM M1\nOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN2LkW3NVUh|ryP MWTTRW5ITVJ?
AN3-CA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPJTWM2OD1|NT6wOVY5KM7:TR?= NV7CPYhvW0GQR1XS
NCI-H1734 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnDeGV4UUN3ME2zOU4zPTZzIN88US=> MVTTRW5ITVJ?
Ca-Ski MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN3LkSxNFEh|ryP MkLXV2FPT0WU
U-266 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3wTWM2OD1|NT62NVE1KM7:TR?= M1WyN3NCVkeHUh?=
SBC-5 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u3XmlEPTB;M{WuO|c5OSEQvF2= Mnr4V2FPT0WU
GT3TKB NITHbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN5LkGxOUDPxE1? M4fCeHNCVkeHUh?=
MDA-MB-175-VII MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HrUGlEPTB;M{euNlI1QCEQvF2= MVTTRW5ITVJ?
PFSK-1 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGyTnBKSzVyPUO3MlI1OzVizszN MnnaV2FPT0WU
IMR-5 M1\EVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHnT|dKSzVyPUO3MlI1QDdizszN MknRV2FPT0WU
Daudi MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnywTWM2OD1|Nz6zOVk4KM7:TR?= NW\mU3JKW0GQR1XS
A498 NY\UfYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;2VmlEPTB;M{euO|IyQCEQvF2= NG\adIhUSU6JRWK=
SCC-4 NIK2d|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHjU|FwUUN3ME2zO{44QDR|IN88US=> NV31dWlHW0GQR1XS
COLO-680N Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzPbnFKSzVyPUO4MlI5QDVizszN NF6xVVVUSU6JRWK=
SK-MES-1 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS2TWM2OD1|OD6zNlE2KM7:TR?= MXrTRW5ITVJ?
SR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vsU2lEPTB;M{iuOVQ6PSEQvF2= M13kW3NCVkeHUh?=
LNCaP-Clone-FGC MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTRTWM2OD1|OD61OlM4KM7:TR?= NU\wU2d2W0GQR1XS
SK-HEP-1 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjxcWJKSzVyPUO4Mlc5OjJizszN NF;hSWVUSU6JRWK=
BPH-1 NHHmd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLsRm1KSzVyPUO4Mlg{OjlizszN MWLTRW5ITVJ?
NCI-H1755 NWjLfohkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64VIJ5UUN3ME2zPU42QDF5IN88US=> NHPXV29USU6JRWK=
LXF-289 M2TJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLCWnRwUUN3ME2zPU45ODh2IN88US=> NXfIOpl7W0GQR1XS
SW1088 M4rpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nzdGlEPTB;NECuNlExPyEQvF2= MoC3V2FPT0WU
MOLT-4 NYjJNlJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETEWHBKSzVyPUSwMlI6ODFizszN M1Xq[3NCVkeHUh?=
AsPC-1 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTwTWM2OD12MD60OVg{KM7:TR?= NGmycm1USU6JRWK=
HOP-62 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHre5VKSzVyPUSwMlY2PjhizszN NX3RWHBrW0GQR1XS
A172 M{fsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRyLki1NVEh|ryP MoGyV2FPT0WU
SN12C MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rzO2lEPTB;NECuPVM5PSEQvF2= NGi3RZZUSU6JRWK=
MDA-MB-231 NX;UdVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\zSWpKSzVyPUSwMlk5QThizszN NUHHUGJZW0GQR1XS
RPMI-2650 M4XuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz2b4RiUUN3ME20NU4yPTl|IN88US=> NV7iZmN{W0GQR1XS
KYSE-140 NV3LbJNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRzLkixNlMh|ryP MUTTRW5ITVJ?
KINGS-1 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\OOVBHUUN3ME20Nk41Pjl5IN88US=> MY\TRW5ITVJ?
HSC-3 NXjuRmZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR{Lk[2OlEh|ryP MVHTRW5ITVJ?
PC-14 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jxN2lEPTB;NEOuNVg5OiEQvF2= MmPxV2FPT0WU
COR-L105 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXDTWM2OD12Mz62OVAzKM7:TR?= MoDqV2FPT0WU
BE-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTR2LkKzO|Eh|ryP MXjTRW5ITVJ?
NCI-H661 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nu[2lEPTB;NESuNlk2QCEQvF2= MYDTRW5ITVJ?
IST-MEL1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXvPVVKSzVyPUS0MlM2QTlizszN NUjXUY4{W0GQR1XS
HCC1806 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyxXVFKSzVyPUS0MlU5PzNizszN MmXMV2FPT0WU
COLO-800 M3rCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTSSoNbUUN3ME20OE45PDV|IN88US=> MoPwV2FPT0WU
IST-SL2 NVnXU4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPCO|ZKSzVyPUS1MlEzPDdizszN M3LvZnNCVkeHUh?=
8305C NULjd2FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLac5RmUUN3ME20OU4{ODlizszN NIjSWnVUSU6JRWK=
UACC-62 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW4[IdKSzVyPUS2MlI5PzVizszN MYXTRW5ITVJ?
COR-L23 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjsXHlKSzVyPUS3MlE6QSEQvF2= M4K0OnNCVkeHUh?=
EFE-184 M1rENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTR5LkO4PEDPxE1? NFTOOWFUSU6JRWK=
DMS-114 M{DhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jEVWlEPTB;NEeuOFE1QSEQvF2= NHn2e2lUSU6JRWK=
KYSE-520 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTNT5dpUUN3ME20PE42OzF3IN88US=> NHG3UZdUSU6JRWK=
SNG-M NX7NcXF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfseo1MUUN3ME20PU41OzRizszN NYPzR5NHW0GQR1XS
A2058 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[zNGlEPTB;NEmuOFg5PSEQvF2= M2\1bHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID